Short Interest in Genfit S.A. (NASDAQ:GNFT) Increases By 6.0%

Genfit S.A. (NASDAQ:GNFTGet Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 63,400 shares, a growth of 6.0% from the December 31st total of 59,800 shares. Based on an average trading volume of 10,100 shares, the short-interest ratio is currently 6.3 days. Approximately 0.1% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Genfit in a report on Friday, October 11th.

View Our Latest Research Report on Genfit

Genfit Stock Down 2.9 %

Genfit stock opened at $3.74 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. Genfit has a 12-month low of $3.35 and a 12-month high of $6.42. The firm has a 50 day moving average of $3.78 and a 200 day moving average of $4.44.

Genfit Company Profile

(Get Free Report)

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

Featured Articles

Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.